Premium
Midwest Cooperative Group evaluation of piposulfan (A‐20968) in cancer
Author(s) -
Nelson N. A.,
Talley R. W.,
Reed M. L.,
Evans A. M.,
Isaacs Bertha L.,
Huffman Philip,
Louis John
Publication year - 1967
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196783385
Subject(s) - medicine , cancer , gastroenterology , multiple myeloma , acute leukemia , drug , vinblastine , leukemia , therapeutic effect , chemotherapy , oncology , pharmacology
Piposulfan (Ancyte), a methanesulfonate, alkylating derivative of piperazine, was administered to 594 patients with various types of cancer. The ohjectives of the study were to determine the optimal dose and to evaluate the therapeutic efJicacy of the drug. After preliminary trials with doses ranging from 3 to 1 mg. per kilogram per day, it was decided to use 1 mg. per kilo gram per day as an initial dose in the majority of patients. Various degrees of therapeutie remissions were seen in patients with malignant lymphomas, acute and chronic leukemia, polycythemia, multiple myeloma, adenocarcinomas, epidermoid carcinomas, and various types of sarcomas. However, the magnitude of the therapeutic response appeared to be quantitatively inferior to that obtained with current antitumor drugs in wide usage. Bane marrow depression or gastrointestinal disturhances occltrred in 118 patients, hut the patients responded to dosage ad;ustments.